B[What are the main considerations for the biomedical technologies to be added? Ministry of Commerce's response] On October 16, the spokesperson of the Ministry of Commerce answered reporters' questions on the revision of the "China's Catalog of Export Prohibited and Restricted Technologies". Q: What are the main considerations for the biomedical technologies to be added?
Answer: There are already some biomedical technologies in the current "Catalogue". This time, it is planned to add 5 technologies related to pathogenic microorganisms, cell and gene therapy, and small nucleic acid drugs. The main considerations are as follows:
The first is to safeguard human life, health and safety. Pathogenic microbial technologies are directly related to human health and national biosecurity. Including them in the Catalog and prohibiting their export is an institutional arrangement to safeguard national security and build a biosecurity barrier. It is also an objective need to protect the health of all mankind.
The second is to support China’s biomedical technology to carry out international cooperation in an orderly manner in accordance with laws and regulations. The listing of biomedical technologies this time will exclude or apply convenient measures to important situations of international cooperation. For example, export situations such as external authorization and licensing of relevant technology and process platforms with independent intellectual property rights, and use of relevant technology and processes to provide outsourced R&D and production services are not included in the scope of management; for relevant target discovery and verification technologies with independent intellectual property rights, exports through external authorization and licensing will be subject to convenient measures such as automatic licensing.
The third is to implement the concept of a human health community. This policy clearly stipulates that for exports of restricted technologies that are required for public health emergencies, humanitarian relief, use of overseas resources for joint research and development, etc., convenient measures such as automatic licensing are applicable. China will continue to share its technological development achievements with other countries around the world and make positive contributions to improving human health and well-being. B[What is the scope of new technologies proposed in China’s Catalog of Technologies Prohibited and Restricted from Exporting? Ministry of Commerce's response] On October 16, the spokesperson of the Ministry of Commerce answered reporters' questions on the revision of the "China's Catalog of Export Prohibited and Restricted Technologies". Q: What is the scope of new technologies to be added to the Catalog?
Answer: This public solicitation for opinions involves 40 key technologies in the three fields of artificial intelligence, biomedicine, and photovoltaics to be added. Among them, 14 technologies are planned to be banned from export, including: artificial intelligence-driven malicious code generation and mutation technology, cell and gene therapy technology platforms with independent intellectual property rights, perovskite and laminated battery component production technologies, etc.; 26 technologies are planned to be restricted from export, including: artificial intelligence-assisted vulnerability mining technology, universal cell and gene therapy new target discovery and verification technology with independent intellectual property rights, polysilicon engineering technology with a single-line production capacity of ≥30,000 tons/year, etc. The announcement also clarified the circumstances under which convenience measures are applicable. Please refer to the original announcement for details. A[The Ministry of Commerce and the Ministry of Science and Technology plan to revise the "China's Catalog of Prohibited and Restricted Export Technologies" and add some artificial intelligence, biomedicine, and photovoltaic technologies] October 16th, in accordance with the "Foreign Trade Law of the People's Republic of China" and the "People's Republic of China Technology Import and Export Administration Regulations", the Ministry of Commerce and the Ministry of Science and Technology plan to revise the "China's Export Prohibited and Restricted Technologies Catalog" to add some artificial intelligence, biomedicine, and photovoltaic technologies. Upon approval, it is now open to the public for solicitation of opinions, and pre-export registration management of related technologies will be implemented simultaneously.
This public solicitation of opinions involves 40 technologies in three fields: artificial intelligence, biomedicine, and photovoltaics. The field of artificial intelligence includes 23 technologies related to large models, agents, computing power clusters, and information processing; technologies that have entered the public domain through open source, published academic papers, etc. are not included in the scope of management. The field of biomedicine includes five technologies related to cell and gene therapy, small nucleic acid drugs, and pathogenic microorganisms; for external authorization models that do not involve ownership transfer, convenient measures such as automatic licensing are applicable. The photovoltaic field includes 12 technologies related to polysilicon manufacturing, silicon wafer manufacturing, and battery manufacturing; the scope of technical management also includes key and core equipment carrying related technologies. B[AI pharmaceuticals and CRO concepts pick up in the afternoon, Berry Genetics 6 days and 3 boards] On October 9th, AI pharmaceuticals and CRO concepts picked up in the afternoon, Berry Genes went straight up to the daily limit, out of 6 days and 3 boards, Technomax rose by more than 10%, Jinshi Yaoyao, Tuojing Life, InnoCare, Shenzhou Cells, etc. quickly surged higher. According to the news, Isomorphic Labs, an AI drug research and development start-up, is advancing preliminary negotiations for a new round of financing. The post-investment valuation of this round is at least US$40 billion, and is expected to reach a maximum of US$50 billion. B[Shanghai Proof-of-Concept Platform Alliance Established] On September 12th, during the Science and Industry Integration Ecological Seminar of the 2026 Pujiang Innovation Forum Results Release held on September 12, the Shanghai Proof-of-Concept Platform Alliance was officially established. It was learned from the Shanghai Municipal Science and Technology Commission that the first batch of members of the alliance consists of 33 proof-of-concept platforms and future industry funds, covering future industrial fields such as brain-computer interfaces, silicon light, cell and gene therapy, as well as key industrial directions such as integrated circuits, intelligent manufacturing, and green technology. The alliance will promote the platform from "fighting independently" to "making a fist with fingers", focusing on capacity sorting, resource sharing, standard formulation, talent cultivation and other work, establishing a mutual recommendation and joint verification mechanism for projects, and accelerating the expansion of the platform matrix. (China Business News) B[Inner Mongolia: Accelerate the progress of African swine fever vaccine research and development] On September 11, the General Office of the People's Government of the Inner Mongolia Autonomous Region recently issued the "Action Plan for Accelerating the High-Quality Development of the Biomanufacturing Industry in the Inner Mongolia Autonomous Region." It is proposed to enhance the core competitiveness of biomedicine. Accelerate the establishment and operation of platforms such as the Hohhot Bio-Intelligent Manufacturing Valley, focus on nucleic acid drugs, cell and gene therapy, "AI + medicine" and other characteristic new tracks, and promote the biomedical industry to leapfrog from scale advantages to technology leadership. Consolidate and enhance the global market leading position of animal vaccine products such as foot-and-mouth disease vaccine, accelerate the research and development of African swine fever vaccines, strengthen the promotion and application of new vaccines and multi-linked multivalent vaccines in the region, and improve the prevention and control capabilities of major animal diseases. Leverage the platform advantages of the company's P3 laboratory to accelerate the development and industrialization of cutting-edge products such as mRNA vaccines and mucosal vaccines, and build a world-leading intelligent manufacturing benchmark for animal vaccines. Deepen the secondary development of traditional Chinese medicine (Mongolian medicine), use synthetic biology technology to enable the discovery and efficient preparation of functional components of characteristic Chinese medicine (Mongolian medicine), and create a modern traditional Chinese medicine (Mongolian medicine) industrial system with Inner Mongolian characteristics.
— All loaded —
